Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trevi Therapeutics, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing Haduvio, oral nalbuphine ER, for chronic cough indications including IPF-related chronic cough, non-IPF interstitial lung disease, and refractory chronic cough. Its 8-K filings report financial results, clinical development updates, FDA meeting disclosures, and material events related to the Haduvio program.
The company’s SEC record also includes registration and offering materials for common stock financings, underwriting agreements, and proxy disclosures covering director elections, executive compensation, governance matters, and equity-based compensation. These filings describe Trevi’s capital structure, development-stage operating profile, and public-company governance.
Trevi Therapeutics director Edward T. Mathers received a new stock option grant covering 35,000 shares of common stock. The nonstatutory option has an exercise price of $13.45 per share and expires on June 2, 2036.
According to the terms, the option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as Mathers continues to serve as a director, employee, or consultant of Trevi Therapeutics.
Trevi Therapeutics, Inc. reported results of its 2026 annual stockholder meeting, where investors approved several governance and capital measures. Stockholders adopted an Amended and Restated 2019 Stock Incentive Plan, adding 8,000,000 shares of common stock for future equity awards and tightening rules on director pay, share recycling, and dividend treatment on awards.
They also approved an amendment to the restated certificate of incorporation to increase authorized common shares from 200,000,000 to 400,000,000, which became effective upon filing a Certificate of Amendment in Delaware on June 3, 2026. Stockholders elected Michael Heffernan as a Class I director through the 2029 annual meeting, ratified Ernst & Young LLP as independent auditor for the 2026 fiscal year, and gave advisory approval to executive compensation.
Trevi Therapeutics director Dominick Colangelo received a new stock option grant. On the reported date, he was granted a nonstatutory option to buy 35,000 shares of Trevi Therapeutics common stock at an exercise price of $13.45 per share.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as he continues to serve as a director, employee or consultant. Following this grant, he holds 35,000 stock options directly.
Trevi Therapeutics, Inc. director David P. Meeker received a grant of a nonstatutory stock option covering 35,000 shares of common stock. The option has an exercise price of $13.45 per share and expires on June 2, 2036.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting held after that date, subject to his continued service as a director, employee or consultant. Following this grant, Meeker holds 35,000 derivative securities directly.
Trevi Therapeutics director Anne Vanlent received a grant of stock options covering 35,000 shares of common stock. The nonstatutory options have an exercise price of $13.45 per share and expire on June 2, 2036. All 35,000 underlying shares are scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders, as long as she continues serving as a director, employee or consultant. Following this award, her reported derivative holdings from this grant total 35,000 options, reflecting a routine compensation-related acquisition rather than an open-market purchase.
Trevi Therapeutics director Michael Thomas Heffernan received a grant of stock options covering 35,000 shares of common stock. The nonstatutory stock option has an exercise price of $13.45 per share and expires on June 2, 2036. The award was granted for his service as a director and will fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting, as long as he continues serving the company. Following this grant, he holds 35,000 options directly under this award.
New Enterprise Associates–affiliated funds filed Amendment No. 9 to update their ownership in Trevi Therapeutics, Inc. after dilution from additional shares outstanding. As of May 5, 2026, the funds may be deemed to beneficially own 15,074,080 common shares, representing 10.5% of Trevi’s stock.
NEA 16 holds 12,273,280 common shares plus 1,851,852 shares underlying NEA 16 warrants, while NEA 18 Venture Growth Equity holds 948,948 shares. The filing states no reportable transactions by these holders in the last 60 days and describes the position as held for investment purposes, with no specific plans to change Trevi’s control or corporate structure.
FMR LLC amended its Schedule 13G to report beneficial ownership of 8,038,060.69 shares of Trevi Therapeutics common stock, representing 6.3% of the class.
The filing shows Abigail P. Johnson has sole dispositive power over the same share amount, references Exhibit 99 for a 13d-1(k)(1) agreement, and attaches a power of attorney effective April 13, 2026.
Trevi Therapeutics reported a net loss of $13.2 million for the three months ended March 31, 2026, compared with $10.3 million a year earlier, as it advances its chronic cough drug Haduvio. Research and development expenses rose to $9.9 million, driven by Phase 3 preparation in idiopathic pulmonary fibrosis (IPF), Phase 2b work in refractory chronic cough (RCC) and NDA‑supportive studies, while general and administrative costs increased to $5.0 million.
The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities, and subsequently strengthened its balance sheet through an April 2026 underwritten equity offering that generated gross proceeds of $173.4 million and approximately $162 million in net proceeds. Management believes existing resources will fund operations for at least 12 months as Trevi progresses parallel Phase 3 IPF-related chronic cough trials, a Phase 2b RCC trial, a Phase 2b non‑IPF ILD trial and multiple Phase 1 studies.
Trevi Therapeutics, Inc. reported a first quarter 2026 net loss of $13.2 million, or $0.09 per share, as it increased investment in its chronic cough pipeline. Research and development and general and administrative expenses both rose versus the prior-year period.
The company ended the quarter with $171.8 million in cash, cash equivalents and marketable securities and then completed an underwritten common stock offering in April 2026 that generated approximately $162 million in net proceeds. Trevi now expects its cash runway to extend into 2030, supporting Phase 3 trials in IPF-related chronic cough, Phase 2b trials in non-IPF ILD-related chronic cough and refractory chronic cough, and a potential FDA submission for Haduvio.